살부타몰황산염

Salbutamol Sulfate

원료 코드 M223069 국내 제품 5개 (단일제 5 · 복합제 0) DUR 성분 D000137

🌐 미국 FDA 자료(영문 라벨·부작용 보고·리콜)가 있습니다. 한국어는 AI 번역 참고용이니 원문을 함께 확인하세요. 해외 정보 보기

⚠️ DUR 안전사용 기준

  • 🤰 임부금기 2등급 임부에 대한 안전성 미확립. 동물실험에서 기형발생이 보고됨.(정제/서방정/서방성필름코팅정/서방성당의정/서방성다층정/서방성장용필름코팅정)
  • 🔁 효능군중복 효능군: 호흡기관용약 · 베타수용체 효능제

이 성분만 든 제품 (단일제 5)

광고

병용금기 성분 (2)

아래 성분이 든 약과 함께 쓰면 안 됩니다 (식약처 DUR).

상대 성분이유
노르에피네프린부정맥 또는 심정지
에피네프린부정맥 또는 심정지

🌐 해외(미국) 정보 — 살부타몰황산염

미국 FDA·NLM 자료 · 2026-10-03 기준

이 성분은 한국어 번역이 없습니다(검수 전 자동 번역 게시는 멈춰 두었습니다). 아래는 미국 FDA 원문입니다 — 원문 라벨(DailyMed).

미국에서 쓰이는 곳(적응증)

영어 원문 (미국 FDA 라벨)

Albuterol Sulfate Inhalation Aerosol is a beta 2 -adrenergic agonist indicated for: Treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. ( 1.1 ) Prevention of exercise-induced bronchospasm in patients 4 years of age and older. ( 1.2 ) 1.1 Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease. 1.2 Exercise-Induced Bronchospasm Albuterol Sulfate Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

쓰면 안 되는 경우

영어 원문 (미국 FDA 라벨)

Albuterol Sulfate Inhalation Aerosol is contraindicated in patients with a history of hypersensitivity to albuterol and any other Albuterol Sulfate Inhalation Aerosol components. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate [see Warnings and Precautions ( 5.6 ) ] . Hypersensitivity to albuterol and any other Albuterol Sulfate Inhalation Aerosol Components.

주요 경고·주의

영어 원문 (미국 FDA 라벨)

Life-threatening paradoxical bronchospasm may occur. Discontinue Albuterol Sulfate Inhalation Aerosol immediately and treat with alternative therapy. ( 5.1 ) Need for more doses of Albuterol Sulfate Inhalation Aerosol than usual may be a sign of deterioration of asthma and requires reevaluation of treatment. ( 5.2 ) Albuterol Sulfate Inhalation Aerosol is not a substitute for corticosteroids. ( 5.3 ) Cardiovascular effects may occur. Use with caution in patients sensitive to sympathomimetic drugs and patients with cardiovascular or convulsive disorders. ( 5.4 , 5.7 ) Excessive use may be fatal. Do not exceed recommended dose. ( 5.5 ) Immediate hypersensitivity reactions may occur. Discontinue Albuterol Sulfate Inhalation Aerosol immediately. ( 5.6 ) Hypokalemia and changes in blood glucose may occur. ( 5.7 , 5.8 ) 5.1 Paradoxical Bronchospasm Albuterol Sulfate Inhalation Aerosol can produce paradoxical bronchospasm that may be life threatening. If paradoxical bronchospasm occurs, Albuterol Sulfate Inhalation Aerosol should be discontinued immediately and alternative therapy instituted. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister. 5.2 Deterioration of Asthma Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol Sulfate Inhalation Aerosol than usual, this may be a marker of …

임신·특수 환자

영어 원문 (미국 FDA 라벨)

8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to asthma medications during pregnancy. For more information, contact the Mothers To Baby Pregnancy Studies conducted by the Organization of Teratology Information Specialists at 1-877-311-8972 or visit http://mothertobaby.org/pregnancy-studies/. Risk Summary There are no randomized clinical studies of use of albuterol during pregnancy. Available data from published epidemiological studies and postmarketing case reports of pregnancy outcomes following inhaled albuterol use do not consistently demonstrate a risk of major birth defects or miscarriage. There are …

미국 제품명 VENTOLIN HFA

미국 부작용 보고(FAERS)에 많이 나온 증상

미국 FDA에 접수된 이 성분 관련 보고 296,553건 가운데 많이 적힌 증상입니다. 보고 수는 약 때문이라는 증거가 아니며, 많이 쓰는 약일수록 많아집니다. 증상 이름의 한국어는 AI 번역(참고용)이라 영어 원어를 함께 적었습니다.

  1. 1 호흡 곤란dyspnoea43,066
  2. 2 천식asthma24,904
  3. 3 약효 없음drug ineffective21,983
  4. 4 기침cough20,393
  5. 5 제품 사용 과정의 잘못된 기술wrong technique in product usage process18,920
  6. 6 폐렴pneumonia16,838
  7. 7 피로fatigue16,829
  8. 8 두통headache15,673
  9. 9 오심nausea14,713
  10. 10 천명음wheezing13,810
  11. 11 적응증 외 사용off label use13,663
  12. 12 통증pain12,959

미국 리콜 기록

FDA 리콜(회수) 기록 21건 중 최근 5건 — 특정 회사·제조번호 제품의 회수로, 국내 제품과는 관계없을 수 있습니다.

  • 2025.08.27 · 3등급(경미) · Cipla USA, Inc. Failed Stability Specifications: Out of specification results was observed in Induction Port during the analysis of Particle size distribution at the 12-month time point.
  • 2025.05.28 · 2등급 · AsttraZeneca Pharmaceuticals LP Defective delivery system
  • 2024.05.01 · 2등급 · Cipla USA, Inc. Short fill: Complaints received of less fill volume in respule and few drops of liquid observed in the intact pouch.
  • 2024.01.03 · 2등급 · CARDINAL HEALTHCARE CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
  • 2024.01.03 · 2등급 · CARDINAL HEALTHCARE CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.

출처: 미국 FDA openFDA(라벨·FAERS·리콜), 미국 국립의학도서관 RxNorm · DailyMed 원문 라벨. 한국어는 오픈드럭 서버 AI(gemma)가 자동 번역한 참고용(사람 검수 전)으로 오역이 있을 수 있으니 반드시 원문을 확인하세요.

허가 취소·취하된 제품 1개 신일살부타몰정(SalbutamolSulfate) 신일제약(주)· 진해거담제· 1974년 허가 유효기간만료